Testing trial was terminated earlier due to the adverse side effects. However, there is a lower risk of infection with reduced dose of MTP in Testing 2.
Reduced dose MTP is shown to reduce the risk of kidney failure, but we have to choose our patients carefully to weigh the benefits against side effects.